A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Tumor microenvironment (TME) has been regarded as a critical regulating environment for immune response and tumor growth in recent years. Similar to the interaction between seeds and soil, TME ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

The announcement is anchored by a study published in Biomacromolecules (American Chemical Society, 2026), conducted by MindWalk in a grant-funded collaboration with Eindhoven University of Technology ...

UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...